Results 171 to 180 of about 2,425,230 (388)
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim+5 more
wiley +1 more source
Specific Cytoplasmic Glucocorticoid Hormone Receptors in Hepatoma Tissue Culture Cells
John D. Baxter, Gordon M. Tomkins
openalex +1 more source
113: Specific 3(H) dexamethasone binding to a thymus cytosol receptor and inhibition of RNAsynthesis by glucocorticoids during postnatal development [PDF]
N. van der Meulen+3 more
openalex +1 more source
Glucocorticoid receptor control of transcription: precision and plasticity via allostery
E. Weikum+3 more
semanticscholar +1 more source
Expert perspective: How, When, and Why to Potentially Stop Anti‐resorptive Drugs in Osteoporosis
Osteoporosis is a chronic disease and anti‐resorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used anti‐resorptive treatments bisphosphonates and denosumab have short and longer term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G Saag
wiley +1 more source
Objectives To investigate the effect of prophylactic trimethoprim‐sulfamethoxazole (TMP‐SMX) on the incidence of serious infections in patients with anti‐neutrophil cytoplasmic antibody‐associated vasculitis (AAV). Methods This multicenter cohort study designed to emulate a target trial studied 296 patients with AAV treated with rituximab or ...
Yun Kyu Kim+7 more
wiley +1 more source
Purification of the glucocorticoid receptor from rat liver cytosol.
Örjan Wränge+2 more
openalex +1 more source
Objective To assess the incidence of major adverse cardiovascular events (MACE) in RA patients treated with JAKi, TNF‐inhibitors (TNFi) or biologic Disease‐Modifying Anti‐Rheumatic Drugs with other modes of action (bDMARD‐OMA) in a multi‐country, real‐world population.
Romain Aymon+28 more
wiley +1 more source